AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 34710395 — intervention group
Group type: EXPERIMENTAL
Intervention: Chinese‐contingent learning group (active sucking on a sensor‐equipped pacifier to infant‐directed Mandarin lullabies and readings)
Number of subjects: 41
Study 34710395 — intervention group
Group type: COMPARATOR
Intervention: English‐enrichment control group (passive exposure to English infant‐directed lullabies and readings)
Number of subjects: 41
Study 32968957 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine monotherapy
Number of subjects: 8
Study 32968957 — intervention group
Group type: COMPARATOR
Intervention: Non-gemcitabine arms
Number of subjects: 8
Study 32570015 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus rhamnosus GG
Number of subjects: 90
Study 32570015 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 36209072 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0% phentolamine mesylate ophthalmic solution (PMOS)
Number of subjects: 24
Study 36209072 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 34290573 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioresorbable vascular scaffold (BVS) + optimal medical therapy (OMT)
Number of subjects: 29
Study 34290573 — intervention group
Group type: COMPARATOR
Intervention: Optimal medical therapy (OMT)
Number of subjects: 29
Study 36301512 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily oral nonsteroidal anti-inflammatory drugs (NSAIDs)
Number of subjects: 2361
Study 36301512 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous tanezumab 2.5 mg (every 8 weeks)
Number of subjects: 2361
Study 36301512 — intervention group
Group type: COMPARATOR
Intervention: NSAIDs and tanezumab
Number of subjects: 2361
Study 34863458 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab plus carboplatin chemotherapy
Number of subjects: 93
Study 34863458 — intervention group
Group type: COMPARATOR
Intervention: Bevacizumab
Number of subjects: 93
Study 34863458 — intervention group
Group type: EXPERIMENTAL
Intervention: Cogstate composite score decline
Number of subjects: 93
Study 33327786 — intervention group
Group type: EXPERIMENTAL
Intervention: 11 + S warm-up program performed at least three times a week for eight weeks
Number of subjects: 28
Study 33327786 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 28
Study 33612630 — intervention group
Group type: EXPERIMENTAL
Intervention: Caromma biscuit (100 g/day for 4 weeks)
Number of subjects: 64
Study 33612630 — intervention group
Group type: EXPERIMENTAL
Intervention: Temma biscuit (100 g/day for 4 weeks)
Number of subjects: 64
Study 35881217 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided umbilical venous catheter insertion (US group)
Number of subjects: 53
Study 35881217 — intervention group
Group type: COMPARATOR
Intervention: Standard method of insertion (SD group)
Number of subjects: 53
Study 32966845 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical interval (SI) of 6 weeks
Number of subjects: 3085
Study 32966845 — intervention group
Group type: EXPERIMENTAL
Intervention: Lengthening of SI
Number of subjects: 3085
Study 32966845 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy dose
Number of subjects: 3085
Study 32966845 — intervention group
Group type: EXPERIMENTAL
Intervention: Addition of oxaliplatin to Nad‐CRT
Number of subjects: 3085
Study 35918028 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiny Cargo, Big Deal!/Abróchame Bien, Cuídame Bien (TCBD/ABCB) intervention, which includes motivational interviewing and tailored eHealth components.
Number of subjects: 900
Study 35918028 — intervention group
Group type: COMPARATOR
Intervention: Enhanced usual care (control group).
Number of subjects: 900
Study 34195469 — intervention group
Group type: EXPERIMENTAL
Intervention: Socio-spiritual intervention consisting of four weekly face-to-face sessions focusing on spirituality, social support, and information needs
Number of subjects: 152
Study 34195469 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 152
Study 35242370 — intervention group
Group type: EXPERIMENTAL
Intervention: PLLA sternal pins (Group P)
Number of subjects: 100
Study 35242370 — intervention group
Group type: COMPARATOR
Intervention: Control group without PLLA sternal pins (Group N)
Number of subjects: 100
Study 35242370 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Group P and Group N)
Number of subjects: 100
Study 34048946 — intervention group
Group type: EXPERIMENTAL
Intervention: pembrolizumab
Number of subjects: 1034
Study 34048946 — intervention group
Group type: EXPERIMENTAL
Intervention: second-course pembrolizumab
Number of subjects: 1034
Study 34048946 — intervention group
Group type: COMPARATOR
Intervention: docetaxel
Number of subjects: 1034
Study 32909643 — intervention group
Group type: EXPERIMENTAL
Intervention: apremilast 30 mg b.i.d.
Number of subjects: 69
Study 33044756 — intervention group
Group type: EXPERIMENTAL
Intervention: Ixekizumab every 4 weeks
Number of subjects: 0
Study 33044756 — intervention group
Group type: EXPERIMENTAL
Intervention: Ixekizumab every 2 weeks
Number of subjects: 0
Study 33044756 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 33745731 — intervention group
Group type: EXPERIMENTAL
Intervention: PCV10 (2+1 schedule)
Number of subjects: 250
Study 33745731 — intervention group
Group type: EXPERIMENTAL
Intervention: PCV13 (2+1 schedule)
Number of subjects: 250
Study 33745731 — intervention group
Group type: COMPARATOR
Intervention: Unvaccinated controls
Number of subjects: 250
Study 36351066 — intervention group
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 infection
Number of subjects: 54
Study 36351066 — intervention group
Group type: COMPARATOR
Intervention: Other infectious pathogens
Number of subjects: 54
Study 32554068 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 J/cm2 laser protocol
Number of subjects: 57
Study 32554068 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 J/cm2 laser protocol
Number of subjects: 57
Study 32554068 — intervention group
Group type: COMPARATOR
Intervention: Sham group (control)
Number of subjects: 57
Study 35952621 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Reality (VR)
Number of subjects: 41
Study 35952621 — intervention group
Group type: COMPARATOR
Intervention: Motor Control (MC)
Number of subjects: 41
Study 32122152 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking programs, health newsletters, community leader trainings, teacher and student trainings, health integration into schools
Number of subjects: 239
Study 33534750 — intervention group
Group type: EXPERIMENTAL
Intervention: Radio frequency‐induced heat therapy (RFHT)
Number of subjects: 40
Study 33534750 — intervention group
Group type: EXPERIMENTAL
Intervention: Handheld exothermic crystallization thermotherapy for CL (HECT‐CL)
Number of subjects: 40
Study 33534750 — intervention group
Group type: COMPARATOR
Intervention: Comparison of cure rates between RFHT and HECT-CL
Number of subjects: 40
Study 32135414 — intervention group
Group type: EXPERIMENTAL
Intervention: Chumlea's formulas for the American black population (CBP)
Number of subjects: 1754
Study 32135414 — intervention group
Group type: EXPERIMENTAL
Intervention: Chumlea's formulas for whites (CC)
Number of subjects: 1754
Study 32135414 — intervention group
Group type: EXPERIMENTAL
Intervention: New proposed formula for height estimation
Number of subjects: 1754
Study 34560903 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidomain lifestyle intervention and/or omega-3 supplementation
Number of subjects: 1630
Study 32975202 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban + Verapamil (n=30)
Number of subjects: 128
Study 32975202 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban + Amlodipine (n=51)
Number of subjects: 128
Study 32975202 — intervention group
Group type: COMPARATOR
Intervention: Control group (Rivaroxaban without CCBs, n=47)
Number of subjects: 128
Study 34627853 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 158
Study 34627853 — intervention group
Group type: COMPARATOR
Intervention: Dalteparin
Number of subjects: 158
Study 33245791 — intervention group
Group type: EXPERIMENTAL
Intervention: En bloc transurethral resection (ERBT)
Number of subjects: 123
Study 33245791 — intervention group
Group type: COMPARATOR
Intervention: Conventional transurethral resection (cTURBT)
Number of subjects: 123
Study 33378079 — intervention group
Group type: EXPERIMENTAL
Intervention: Implants without peri-implantitis
Number of subjects: 240
Study 33378079 — intervention group
Group type: EXPERIMENTAL
Intervention: Implants diagnosed with peri-implantitis
Number of subjects: 240
Study 33378079 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk factors for buccal PISTD
Number of subjects: 240
Study 36126864 — intervention group
Group type: EXPERIMENTAL
Intervention: HD-tDCS (F3, F4)
Number of subjects: 11
Study 36126864 — intervention group
Group type: COMPARATOR
Intervention: SHAM
Number of subjects: 11
Study 36370741 — intervention group
Group type: EXPERIMENTAL
Intervention: mDOT
Number of subjects: 755
Study 36370741 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient Navigation
Number of subjects: 755
Study 32957034 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose patellar tendon isometric exercise protocol
Number of subjects: 28
Study 32957034 — intervention group
Group type: COMPARATOR
Intervention: Sham-TENS protocol
Number of subjects: 28
Study 35771546 — intervention group
Group type: EXPERIMENTAL
Intervention: Apatinib plus Pegylated Liposomal Doxorubicin (PLD)
Number of subjects: 152
Study 35771546 — intervention group
Group type: COMPARATOR
Intervention: Pegylated Liposomal Doxorubicin (PLD)
Number of subjects: 152
Study 34377472 — intervention group
Group type: EXPERIMENTAL
Intervention: MagNOVOx™
Number of subjects: 12
Study 34377472 — intervention group
Group type: COMPARATOR
Intervention: Placebo (inulin)
Number of subjects: 12
Study 33385511 — intervention group
Group type: EXPERIMENTAL
Intervention: Ziziphus spinosa (ZS) 2 g daily
Number of subjects: 12
Study 33385511 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 32462542 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous dexmedetomidine (1 µg/kg during a 10-min infusion)
Number of subjects: 10
Study 32462542 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous dexmedetomidine (1 µg/kg during a 10-min infusion)
Number of subjects: 10
Study 35536366 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Reverse Step-Cut Osteotomy (MRSO)
Number of subjects: 20
Study 35536366 — intervention group
Group type: COMPARATOR
Intervention: Yun's Reverse V Osteotomy (RVO)
Number of subjects: 20
Study 33964223 — intervention group
Group type: EXPERIMENTAL
Intervention: R21 plus 25 μg MM (Group 1)
Number of subjects: 450
Study 33964223 — intervention group
Group type: EXPERIMENTAL
Intervention: R21 plus 50 μg MM (Group 2)
Number of subjects: 450
Study 33964223 — intervention group
Group type: COMPARATOR
Intervention: Rabies vaccinations (Group 3, Control)
Number of subjects: 450
Study 32291132 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual segmentation method
Number of subjects: 15
Study 32291132 — intervention group
Group type: EXPERIMENTAL
Intervention: Semi-automated segmentation method
Number of subjects: 15
Study 32291132 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated segmentation method
Number of subjects: 15
Study 36343348 — intervention group
Group type: EXPERIMENTAL
Intervention: ENT‐01
Number of subjects: 150
Study 36343348 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study 33544883 — intervention group
Group type: EXPERIMENTAL
Intervention: Tildrakizumab 100 mg
Number of subjects: 677
Study 33544883 — intervention group
Group type: EXPERIMENTAL
Intervention: Tildrakizumab 200 mg
Number of subjects: 677
Study 33544883 — intervention group
Group type: EXPERIMENTAL
Intervention: Tildrakizumab 200 mg (after switching from ETN)
Number of subjects: 677
Study 32881403 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive Lifestyle Intervention (ILI)
Number of subjects: 5490
Study 32881403 — intervention group
Group type: COMPARATOR
Intervention: Diabetes Support and Education (DSE)
Number of subjects: 5490
Study 32881403 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive Lifestyle Intervention (ILI) with increased WC
Number of subjects: 5490
Study 35975564 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginseng (1 g/day)
Number of subjects: 30
Study 35975564 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 33819509 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic Lactobacillus rhamnosus GG administered for 3 months
Number of subjects: 28
Study 33819509 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic Lactobacillus rhamnosus GG
Number of subjects: 28
Study 33819509 — intervention group
Group type: COMPARATOR
Intervention: Patients with APS‐1
Number of subjects: 28
Study 32120316 — intervention group
Group type: EXPERIMENTAL
Intervention: Synbiotic supplementation (two synbiotic capsules daily for 2 months)
Number of subjects: 42
Study 32120316 — intervention group
Group type: COMPARATOR
Intervention: Placebo (maltodextrin)
Number of subjects: 42
Study 35220124 — intervention group
Group type: EXPERIMENTAL
Intervention: QAMS method for quantifying aflatoxins and their precursors
Number of subjects: 0
Study 35220124 — intervention group
Group type: EXPERIMENTAL
Intervention: QAMS method
Number of subjects: 0
Study 33269429 — intervention group
Group type: EXPERIMENTAL
Intervention: MGB/OAGB
Number of subjects: 58
Study 33269429 — intervention group
Group type: COMPARATOR
Intervention: LSG
Number of subjects: 58
Study 35090399 — intervention group
Group type: EXPERIMENTAL
Intervention: Wrist HBPM device
Number of subjects: 100
Study 35090399 — intervention group
Group type: COMPARATOR
Intervention: Arm HBPM device
Number of subjects: 100
Study 35090399 — intervention group
Group type: EXPERIMENTAL
Intervention: More accurate device
Number of subjects: 100
Study 33818939 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrophilic nutrients (BESTFertil dietary supplement, 4 capsules per day)
Number of subjects: 160
Study 33818939 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipophilic nutrients (dietary supplement 'BrudiPlus', 3 capsules per day)
Number of subjects: 160
Study 33818939 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 160
Study 33818939 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrophilic nutrients
Number of subjects: 160
Study 33818939 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipophilic nutrients
Number of subjects: 160
Study 33818939 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 160
Study 33818939 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrophilic and lipophilic nutrients
Number of subjects: 160
Study 34020099 — intervention group
Group type: EXPERIMENTAL
Intervention: Rx for Success (RxS) mobile app
Number of subjects: 252
Study 34020099 — intervention group
Group type: COMPARATOR
Intervention: Control (children's book modeling alternatives to screen time)
Number of subjects: 252
Study 32087922 — intervention group
Group type: EXPERIMENTAL
Intervention: T. orientalis Ikeda type infection
Number of subjects: 10
Study 34478166 — intervention group
Group type: EXPERIMENTAL
Intervention: Niraparib (200 mg once daily) plus Pembrolizumab (200 mg every 3 weeks) in cohort 1
Number of subjects: 38
Study 34478166 — intervention group
Group type: EXPERIMENTAL
Intervention: Niraparib (200 mg once daily) plus Pembrolizumab (200 mg every 3 weeks) in cohort 2
Number of subjects: 38
Study 34478166 — intervention group
Group type: EXPERIMENTAL
Intervention: Niraparib plus Pembrolizumab in cohort 1
Number of subjects: 38
Study 34478166 — intervention group
Group type: EXPERIMENTAL
Intervention: Niraparib plus Pembrolizumab in cohort 2
Number of subjects: 38
Study 34478166 — intervention group
Group type: EXPERIMENTAL
Intervention: Niraparib plus Pembrolizumab in cohorts 1 and 2
Number of subjects: 38
Study 34016868 — intervention group
Group type: EXPERIMENTAL
Intervention: Light rolling cotton swab touch
Number of subjects: 16
Study 34016868 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine 4% topical solution
Number of subjects: 16
Study 34016868 — intervention group
Group type: EXPERIMENTAL
Intervention: Vulvalgesiometer
Number of subjects: 16
Study 34016868 — intervention group
Group type: EXPERIMENTAL
Intervention: Verbal Pain Scale
Number of subjects: 16
Study 36342151 — intervention group
Group type: EXPERIMENTAL
Intervention: Double sequential external defibrillation (DSED)
Number of subjects: 405
Study 36342151 — intervention group
Group type: EXPERIMENTAL
Intervention: Vector-change (VC) defibrillation
Number of subjects: 405
Study 36342151 — intervention group
Group type: COMPARATOR
Intervention: Standard defibrillation
Number of subjects: 405
Study 34496278 — intervention group
Group type: EXPERIMENTAL
Intervention: 12‐weeks of supervised, treadmill walking exercise training
Number of subjects: 11
Study 34496278 — intervention group
Group type: COMPARATOR
Intervention: 12‐weeks of low‐intensity resistive exercise (active control condition)
Number of subjects: 11
Study 32921767 — intervention group
Group type: EXPERIMENTAL
Intervention: Lertal® (nutraceutical)
Number of subjects: 0
Study 32921767 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 0
Study 36347569 — intervention group
Group type: EXPERIMENTAL
Intervention: Meal M2 (rice cooked with coconut oil)
Number of subjects: 20
Study 36347569 — intervention group
Group type: COMPARATOR
Intervention: Meal M1 (rice)
Number of subjects: 20
Study 36347569 — intervention group
Group type: COMPARATOR
Intervention: Meal M3 (rice cooked in coconut oil with lentils)
Number of subjects: 20
Study 34426466 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard diagnostic examination (SDE) plus a CAD‐score
Number of subjects: 2000
Study 34426466 — intervention group
Group type: COMPARATOR
Intervention: Standard diagnostic examination (SDE) according to current guidelines
Number of subjects: 2000
Study 35805371 — intervention group
Group type: EXPERIMENTAL
Intervention: Crockery Set
Number of subjects: 31
Study 35805371 — intervention group
Group type: EXPERIMENTAL
Intervention: Utensil Set
Number of subjects: 31
Study 35805371 — intervention group
Group type: EXPERIMENTAL
Intervention: Both tools
Number of subjects: 31
Study 33464683 — intervention group
Group type: EXPERIMENTAL
Intervention: Strict low FODMAP diet (LFD)
Number of subjects: 101
Study 33464683 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified low FODMAP diet (LFD)
Number of subjects: 101
Study 33464683 — intervention group
Group type: COMPARATOR
Intervention: Traditional dietary advice (TDA)
Number of subjects: 101
Study 35507334 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomacopan, 90 mg subcutaneously on day 1 and 30 mg subcutaneously daily until day 42
Number of subjects: 9
Study 35507334 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomacopan
Number of subjects: 9
Study 34626008 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose rhEPO (40 IU/kg)
Number of subjects: 20
Study 34626008 — intervention group
Group type: EXPERIMENTAL
Intervention: rhEPO micro-doses (900 IU)
Number of subjects: 20
Study 34626008 — intervention group
Group type: EXPERIMENTAL
Intervention: Washout phase after rhEPO administration
Number of subjects: 20
Study 33146720 — intervention group
Group type: EXPERIMENTAL
Intervention: Matrix‐M‐adjuvanted qNIV
Number of subjects: 1375
Study 33146720 — intervention group
Group type: COMPARATOR
Intervention: All treatment groups
Number of subjects: 1375
Study 36001436 — intervention group
Group type: COMPARATOR
Intervention: Alcohol administration (oral and intravenous, variable and fixed doses)
Number of subjects: 0
Study 36001436 — intervention group
Group type: COMPARATOR
Intervention: Individuals with AUD
Number of subjects: 0
Study 33264662 — intervention group
Group type: EXPERIMENTAL
Intervention: Trigeminal nerve stimulation (TNS) for 4 weeks
Number of subjects: 62
Study 33264662 — intervention group
Group type: COMPARATOR
Intervention: Sham control
Number of subjects: 62
Study 35708758 — intervention group
Group type: COMPARATOR
Intervention: Control group (targeted antifungal therapy driven by culture results)
Number of subjects: 339
Study 33431819 — intervention group
Group type: EXPERIMENTAL
Intervention: Arachidonoylcyclopropylamide (ACPA) at IC50 of 1.39 × 10‐12 M
Number of subjects: 0
Study 33431819 — intervention group
Group type: EXPERIMENTAL
Intervention: ACPA-PCL nanoparticle system
Number of subjects: 0
Study 33431819 — intervention group
Group type: COMPARATOR
Intervention: CB1 antagonist AM281
Number of subjects: 0
Study 35143340 — intervention group
Group type: EXPERIMENTAL
Intervention: Postpartum yoga practice (60 minutes, 2 days a week for 8 weeks)
Number of subjects: 124
Study 35143340 — intervention group
Group type: COMPARATOR
Intervention: Control group (no yoga practice)
Number of subjects: 124
Study 33754924 — intervention group
Group type: EXPERIMENTAL
Intervention: Dacomitinib
Number of subjects: 0
Study 33754924 — intervention group
Group type: COMPARATOR
Intervention: Osimertinib
Number of subjects: 0
Study 33754924 — intervention group
Group type: COMPARATOR
Intervention: Afatinib
Number of subjects: 0
Study 32240480 — intervention group
Group type: EXPERIMENTAL
Intervention: KiVa Bullying Prevention Program
Number of subjects: 3214
Study 32240480 — intervention group
Group type: COMPARATOR
Intervention: Usual school provision (waitlist control)
Number of subjects: 3214
Study 32530339 — intervention group
Group type: EXPERIMENTAL
Intervention: Synbiotic (five drops/day)
Number of subjects: 81
Study 32530339 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 (1000 IU daily)
Number of subjects: 81
Study 32530339 — intervention group
Group type: COMPARATOR
Intervention: Control (routine treatments only)
Number of subjects: 81
Study 32948108 — intervention group
Group type: EXPERIMENTAL
Intervention: Analogy learning
Number of subjects: 40
Study 32948108 — intervention group
Group type: COMPARATOR
Intervention: Explicit learning
Number of subjects: 40
Study 32546256 — intervention group
Group type: EXPERIMENTAL
Intervention: IMPROVEjob intervention
Number of subjects: 56
Study 32546256 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list control group
Number of subjects: 56
Study 35389961 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose Levothyroxine
Number of subjects: 199
Study 35389961 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose Methylprednisolone
Number of subjects: 199
Study 35389961 — intervention group
Group type: EXPERIMENTAL
Intervention: Combo (High-dose Levothyroxine + High-dose Methylprednisolone)
Number of subjects: 199
Study 35389961 — intervention group
Group type: COMPARATOR
Intervention: Control (No hormonal therapy)
Number of subjects: 199
Study 32997088 — intervention group
Group type: EXPERIMENTAL
Intervention: GC (glaze on compression side)
Number of subjects: 80